CompletedPhase 2

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

China14 participantsStarted 2022-09-07

Plain-language summary

This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.

Who can participate

Age range3 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosed CD7 positive relapsed/refractory hematological malignancies.
✓. Echocardiography shows left ventricular ejection fraction (LVEF) ≥ 50%;
✓. There is no active pulmonary infection, and the oxygen saturation during air inhalation is more than 92%;
✓. The estimated survival time is more than 3 months;
✓. Eastern cooperative oncology group (ECOG) performance status of 0 to 2
✓. The patients or their legal guardians voluntarily participated in the trial and signed the informed consent.

Exclusion criteria

✕. Patients with history of epilepsy or other central nervous system diseases;
✕. Patients with prolonged QT or severe heart disease;
✕. Pregnant or lactating women
✕. Patients with uncontrolled active infection.
✕. Positive for any of the following etiological tests: HIV, HBV, HCV
✕. Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial

What they're measuring

Overall Response Rate(ORR)

Timeframe: 1 Year

Trial details

NCT IDNCT05454241

SponsorInstitute of Hematology & Blood Diseases Hospital, China

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-31

View on ClinicalTrials.gov More Hematological Malignancies trials